Dose response of umeclidinium administered once or twice daily in patients with COPD: A randomised cross-over study

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Church, Alison ^a   Beerahee, Misba ^b   Brooks, Jean ^b   Mehta, Rashmi ^a   Shah, Palvi ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease (COPD); GSK573719; Long acting bronchodilators; Long acting muscarinic antagonist (LAMA); Umeclidinium (UMEC)

Indexed keywords

PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE; UMECLIDINIUM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MIDDLE AGED; MORNING DOSAGE; MULTICENTER STUDY; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VERY ELDERLY; ACUTE RESPIRATORY FAILURE; DRUG POTENCY; FORCED VITAL CAPACITY; HEART INFARCTION; PATIENT COMPLIANCE;

CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES;

EID: 84891508708     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-2     Document Type: Article

References (22)

1. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:297-304. 10.1513/pats.200504-043SR, 16267352.
2. Roffel AF, Elzinga CR, Zaagsma J. Muscarinic M3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol 1990, 3:47-51. 10.1016/0952-0600(90)90009-8, 2152027.
3. Brusasco V. Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur Respir Rev 2006, 15:32-36.
4. GOLD: Global Initiative for Chronic Obstructive Lung Disease Updated 2013. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf (Accessed January 3, 2014).
5. Cahn A, Tal-Singer R, Pouliquen IJ, Mehta R, Preece A, Hardes K, Crater G, Deans A. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies. Clin Drug Invest 2013, 33:477-488.
6. Donohue J, Anzueto A, Brooks J, Crater G, Mehta R, Kalberg C. A Randomized, double-Blind, dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012, 106:970-979. 10.1016/j.rmed.2012.03.012, 22498110.
7. Tal-Singer R, Cahn T, Mehta R, Preece A, Crater G, Kelleher D, Pouliquen IJ. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: Two randomised studies. Eur J Pharmacol 2013, 701:40-48. 10.1016/j.ejphar.2012.12.019, 23276660.
8. Decramer M, Maltais F, Feldman G, Brooks J, Harris S, Mehta R, Crater G. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013, 185:393-399. 10.1016/j.resp.2012.08.022, 23026438.
9. Sheiner LB, Hashimoto Y, Beal SL. A simulation study comparing designs for dose ranging. Stat Med 1991, 10:303-331. 10.1002/sim.4780100303, 2028115.
10. Church A, Beerahee M, Brooks J, Mehta R, Shah P. Umeclidinium (GSK573719) dose response and dosing interval in COPD [abstract]. Eur Respir J 2012, 40(Suppl 56):377s.
11. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946. 10.1183/09031936.04.00014304, 15219010.
12. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Resp Crit Care Med 1999, 159:179-187. 10.1164/ajrccm.159.1.9712108, 9872837.
13. Hankinson JL, Kawut SM, Shahar E, Smith LJ, Hinckley MD, Stukovsky K, Barr RG. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest 2010, 137:138-145. 10.1378/chest.09-0919, 2803123, 19741060.
14. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 59th WMA General Assembly, Seoul, Korea, October 2008 http://www.wma.net/en/30publications/10policies/b3/index.html (Accessed January 3, 2014).
15. Miller MR, Hankinson J, Brusasco V, Burgos R, Casaburi R. Standardisation for spirometry. Eur Respir J 2005, 26:319-338. 10.1183/09031936.05.00034805, 16055882.
16. Vong C, Bergstrand M, Karlson MO. Rapid sample size calculations for a defined likelihood ratio test-based power in mixed effects models [abstract]. Annu Meet Popul Approach Group Eur 2010, 1863:19.
17. European Medical Agency guidelines Guideline on reporting the results of population pharmacokinetic analyses. CHMP/EWP/185990/06 2007, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003067.pdf (Accessed January 3, 2014), European Medical Agency guidelines.
18. Food and Drug Administration (FDA) Guidance for industry: population pharmacokinetics 1999, U.S. Center for Drug Evaluation and Research, http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133184.pdf (Accessed January 3, 2014), Food and Drug Administration (FDA).
19. Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res 2011, 12:54. 10.1186/1465-9921-12-54, 3102616, 21518459.
20. Wang Y, Lee JY, Michele T, Chowdhury BA, Gobburu JV. Limitations of model based dose selection for indacaterol in patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther 2012, 50:622-630. 10.5414/CP201758, 22578206.
21. Lainé DI, Luttmann MA, Foley JJ, Dehaas CJ, Kotzer CJ, Salmon M, Rumsey WL. The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing [abstract]. Eur Respir J 2011, 38(Suppl 55):613s.
22. Pfizer Inc Spiriva HandiHaler prescribing information 2006, New York, NY, USA, http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Spiriva/Spiriva.pdf (Accessed January 3, 2014), Pfizer Inc.